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Abstract Many assays to evaluate the nature, breadth, and
quality of antigen-speciWc T cell responses are currently
applied in human medicine. In most cases, assay-related
protocols are developed on an individual laboratory basis,
resulting in a large number of diVerent protocols being
applied worldwide. Together with the inherent complexity
of cellular assays, this leads to unnecessary limitations in the
ability to compare results generated across institutions. Over
the past few years a number of critical assay parameters
have been identiWed which inXuence test performance irre-
spective of protocol, material, and reagents used. Describing
these critical factors as an integral part of any published
report will both facilitate the comparison of data generated
across institutions and lead to improvements in the assays
themselves. To this end, the Minimal Information About T
Cell Assays (MIATA) project was initiated. The objectiveC. M. Britten and S. Janetzki contributed equally.
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16 Cancer Immunol Immunother (2011) 60:15–22of MIATA is to achieve a broad consensus on which T cell
assay parameters should be reported in scientiWc publica-
tions and to propose a mechanism for reporting these in a
systematic manner. To add maximum value for the scientiWc
community, a step-wise, open, and Weld-spanning approach
has been taken to achieve technical precision, user-friendli-
ness, adequate incorporation of concerns, and high accep-
tance among peers. Here, we describe the past, present, and
future perspectives of the MIATA project. We suggest that
the approach taken can be generically applied to projects in
which a broad consensus has to be reached among scientists
working in fragmented Welds, such as immunology. An
additional objective of this undertaking is to engage the
broader scientiWc community to comment on MIATA and to
become an active participant in the project.
Keywords Minimal information about T cell assays · 
Reporting guidelines · Immune monitoring · MIATA
Introduction
For many years, the development of active immunotherapy
to treat cancer was considered a pursuit with uncertain out-
come that was met by increasing skepticism, in part result-
ing from failure to demonstrate clinical eYcacy [1, 2].
Recent reports of success from randomized phase III trials
[3–5] and the Wrst approval for a therapeutic vaccine [6]
now set the stage for a new era of immunotherapy with
greater availability of biological samples from large con-
trolled clinical trials on the horizon. A crucial role for T cell
responses in active immunotherapy has been demonstrated
in numerous animal models as well as in clinical trials [7,
8]. A large number of diVerent assays for measuring T cell
quality and function has been developed and applied in
such clinical trials. The identiWcation, development, and
eventual validation of T cell biomarkers that correlate with
product bioactivity and clinical response is a challenging
and complex process, but is required for understanding and
improving on response rates. This necessitates an integrated
clinical development plan, a systematic and comprehensive
standardized scheme for sample procurement/processing,
and biomarker assays including data analysis to be applied.
To this end, quality-enabling laboratory infrastructure
needs to be established, which is essential for large and
well-conducted trials, culminating in the enhanced potential
to measure successful induction of clinical responses [9,
10]. Because the technical validation of assays for measur-
ing cellular immune biomarkers is not trivial, systematic
mono- and multi-center eVorts have been initiated in the
diVerent Welds of cancer immunology, autoimmunity and
infectious diseases to harmonize and standardize T cell
assays. These systematic eVorts have led to the identiWca-
tion of critical factors that inXuence assay performance and
the consequent formulation of guidelines to improve and
harmonize T cell assays across laboratories [11–16]. These
harmonization eVorts increased the awareness to the prob-
lem that, despite the vast body of literature describing
results from T cell assays, the majority of scientiWc publica-
tions lack important information on crucial steps in the
assay process, precluding a full understanding and accurate
interpretation of published data sets and limiting the ability
to reproduce results and compare data sets between centers
or perform meta-analysis. Undoubtedly, having a more uni-
form and complete reporting structure would not only serve
the broad interests of the scientiWc community, but would
also be beneWcial in enhancing the accurate communication
of methodologies between immunotherapy programs.
In 2008, a core team of immunologists from Europe and
the United States embarked on the establishment of a Mini-
mal Information (MI) project for T cell assays and set the
stage for an ongoing large-scale, Weld-spanning eVort to
generate a widely acceptable reporting framework to sup-
port scientiWc publications and enhance the utility of pre-
sented data. The project on Minimal Information About T
Cell Assays (MIATA) was announced in October 2009
[17]; and a dedicated web site was launched in parallel with
the listing of a Wrst draft of guidelines, consisting of Wve
modules based on the gained knowledge from harmoniza-
tion eVorts about factors that critically inXuence assay
results, namely the requirement to provide information on
the (1) sample, (2) the assay, (3) data acquisition, (4) the
interpretation of data as well as (5) the lab environment
[18]. At the same time, a public consultation phase was ini-
tiated. Since then, based primarily on the input from the
public consultation process and public workshops, the
MIATA project has undergone a process of evolution and
maturation, resulting in a streamlined set of guidelines for
reporting on T cell assays. These guidelines can be found
on the MIATA website (http://www.miataproject.org).
Here, we elaborate on the ongoing collaborative approach
taken to develop MIATA guidelines, which was found to
be essential in order to achieve the desired high degree
of quality and acceptability for T cell assays. The process
also led to the identiWcation of critical factors for success
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science.
Minimal information projects
The concept of Minimal Information projects was pio-
neered by Brazma et al. [19], for complex analytical assays
that generate large data sets with several layers of informa-
tion, to meet demands in the area of microarrays. Subse-
quently, the Wrst successful MI project addressing
microarray experiments was introduced [20]. Meanwhile
over 30 MI projects for diVerent types of assays have been
proposed, many of which are listed under the MIBBI portal,
which provides assistance to investigators in identifying
suitable MI guidelines for their work [21]. Most MI pro-
jects are (1) primarily designed for high-throughput assays
and (2) require detailed annotation of samples and related
data sets to populate large databases and allow for data
mining by third parties. The majority of current T cell
assays do not fall under the category “high throughput”,
and current data sharing refers mainly to comparing results
from diVerent groups working in similar areas, rather than
exploring existing data sets generated by third parties. The
introduction of new technologies in the immune assay Weld
might change this situation [22, 23], and applicable MI pro-
jects including MIATA need to be adaptable and expand-
able for data mining, for example in an envisioned Human
Immunity Project [24]. It should be noted that a minimal
information framework for publications might signiWcantly
diVer from a framework for populating large databases
including content and syntax [25].
What is MIATA?
MIATA is a framework for WHAT and HOW to report
when publishing immune monitoring tests and results. The
overall goal for MIATA is to provide the reader with the
minimal information necessary to understand how reported
data related to T cell assays were generated [26]. This is
accomplished by providing a structured basis for reporting
the information that allows the full and objective evaluation
of the presented data sets, as well as for the ability to inte-
grate data sets across studies. MIATA focuses solely on the
reporting content and structure for assays, not the assay
content and structure.
What MIATA is not
MIATA is not an eVort to impose speciWc standards on how
T cell assays are performed, including assay standardiza-
tion, validation, and setup of the appropriate laboratory
environment. MIATA is without prejudice on how and
when immune monitoring is performed. These issues need
to be addressed by the individual investigators before a
study is initiated. Consequently, conformity to the MIATA
guidelines does not require the use of standardized assay
protocols or a certain laboratory setup. Freedom of research
and Xexibility in the choice of assays and reagents used are
of utmost importance and must not be limited at any time
by any MI project.
Minimal information projects with overlap
Several MI projects with some degree of overlap with
MIATA exist, for example Minimal Information About a
Cellular Assay (MIACA) [27], Minimum Information for a
Flow Cytometry Experiment (MIFlowCyt) [28], the Publi-
cation on Publishing Flow Cytometry Data [29] and
Reporting recommendations for tumor Marker prognostic
studies (REMARK) [30]. Each of these projects is unique,
and all are based on the expertise and input of highly expe-
rienced investigators. The REMARK criteria from the Sta-
tistics Subcommittee of the NCI-EORTC Working Group
on Cancer Diagnostics have achieved a notable level of
awareness in the community, supported by parallel publica-
tions in and endorsement by several international journals.
Although REMARK has proven its value in several prog-
nostic biomarker study publications [31], it does not spe-
ciWcally address aspects unique to T cell assays. Further,
publications that claim conformity to other MI projects
with overlap to MIATA are sparse at most. This might be
partially due to the overwhelming amount of information
required by other MI projects that were designed primarily
to support data mining. These circumstances provide the
foundations for the two-step approach introduced here with
the initial focus on scientiWc publications, and later expand-
ability for data mining. Such a process has the potential for
wide acceptance and a successful adoption rate of MIATA,
as it could for other MI projects.
Factors for success
Several major challenges exist for activities that aim to
impact current practices and achieve broad consensus
among scientists who work in fragmented Welds of science
(Table 1).
To begin, implementation of a new process (e.g., struc-
tured framework to report data from analytical assays such
as MIATA) in a lab environment is time-consuming. It
requires investigators to read, understand and approve the
new framework internally, to teach staV members to apply123
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Consequently, any new reporting framework proposed to
the Weld has to Wnd a balance between being easy to under-
stand and implement and requesting an amount of informa-
tion suYcient to fulWll its purpose. Clearly, MI projects
should be as “minimal” as possible. However, while mini-
mizing the content of a reporting framework beyond a cer-
tain degree might make it easier to implement, it can also
decrease its value signiWcantly. Achieving the appropriate
balance between not asking for too much or too little infor-
mation has been and still is one of the most diYcult tasks in
the evolution of the MIATA project and is the focus of
many discussions among the investigators involved.
Clearly, the additional workload associated with implemen-
tation of MIATA should never outweigh its added value for
individual investigators and the scientiWc community.
Even a user-friendly and technically precise reporting
framework will not be of any value unless broadly accepted
and adopted by scientists and journals. An investigator’s
decision to accept or reject a proposed reporting framework
will critically depend on the absence or existence of any
concerns related to conforming to the guidelines. Various
concerns were also raised after the Wrst draft of MIATA
(version 0) was published. It became clear that speciWc con-
cerns were typically shared by groups of colleagues with a
similar focus of their work (e.g., assay validation, research
labs, labs performing correlative studies in larger clinical
trials, applicants for funding schemes). Part of the MIATA
approach has been to carefully consider and address each of
these concerns en route to establishing a Wnal set of report-
ing guidelines.
Finally, the adoption of MIATA will crucially depend on
knowledge of the framework and its acceptance as standard
practice by peers and stakeholders in the Weld. Despite the
overwhelming redundancy in the nature of the assays used
to evaluate immune responses across specialized Welds such
as cancer immunology, autoimmunity, transplantation, and
infectious diseases, scientists in each of those Welds have
historically tended to operate as more or less isolated
groups, developing closely related assays in a parallel,
often redundant, fragmented, and non-integrated manner.
Geographic fragmentation, facilitated by the establishment
of specialty societies in the USA, Europe, parts of Asia, and
Australia has further added to the non-integrated nature of
T cell assay development. This fragmentation clearly needs
to be addressed and overcome by integrating the expertise
from as many directly involved peers as possible into the
framework, independent of location, aYliation or back-
ground.
The past, presence, and future of MIATA
Many MI projects are authored by a signiWcant number of
scientists, and the process of reaching a consensus through
discussions and seminars is a hallmark of most, if not all of
them. On closer examination, the consensus-building pro-
cess commonly appears to be conWned to a group of
experts, and it is not always clear at what level peers were
involved.
The vision of the MIATA core team was to reach out to
as many colleagues as possible in diVerent areas of immu-
nology and in laboratories involved in research and clini-
cal trial monitoring. We believe that contributors to the
process should include the scientists performing the assay,
as well as principal investigators, regulatory authorities,
and journal editors. Since its initial phase, the MIATA pro-
ject has been working towards integrating suggestions
and criticism from experts representing diVerent areas of
immunology, and from societies across geographic bound-
aries; accordingly, primary authors on this manuscript are
active participants and members of a wide range of immu-
nology associations. MIATA never was or shall be a
closed community excluding individual colleagues or
groups. On the contrary, the core team is pursuing a bot-
tom-up approach and is reaching out to an increasing num-
ber of colleagues to integrate expertise into the framework
from as many directly involved peers as possible and
thereby make them an integral and important part of the
MIATA project.
Transparency at every level and step, open access to any
communication and ongoing discussion, and Xexibility dur-
ing the maturation process were key process features for
MIATA from the beginning. Important components of the
MIATA maturation process are (Fig. 1).
1. An independent project web site (http://www.miatapro-
ject.org)
2. An expanding network of supporting organizations
3. A public consultation period on the initial guideline
draft (Version 0)
4. A public workshop and follow-up webinars
5. A public consultation period on the updated guidelines
(Version 1)
6. A concluding workshop to consolidate the publication
framework.
Table 1 Factors of success
Factors of success for MI projects
Technically precise (captures all essential information of the assay)
User-friendly (truly minimal and clearly understandable)
No existing concerns to prevent conforming
Accepted by peers
Added value to user/community123
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tool for the transparent recording of MIATA’s progress. It
proved to be an eYcient tool for the ongoing consultation
period during which each comment and responses to those
comments were posted. The web site itself is run indepen-
dently of any organization or other web site.
Public consultation period, workshop, and webinars
An important factor for the advancement of the MIATA
process was the support and patronage received early on by
organizations, namely the Cancer Immunotherapy Consor-
tium of the Cancer Research Institute (CIC/CRI) and the
Association of Cancer Immunotherapy (CIMT), the Human
Immune Monitoring Center at Stanford, and the Italian Net-
work for Biotherapy of Cancer (NIBIT). During the public
consultation period, investigators active in the Weld were
asked to comment on the initial draft of the MIATA guide-
lines. Within 5 months, 54 comments were posted from
over 80 contributors from 14 countries, from diverse Welds
and backgrounds. The comments received were construc-
tive and supportive, and could be divided into two main
categories:
a. comments on the MIATA modules focusing on the
speciWc content of each module and sub-module; and
b. comments on the overall focus and intent of
MIATA, including logistics for its feasibility and
applicability.
All comments were reviewed and considered in light of the
module, sub-module, and general topic addressed, and the
overall messages distilled and summarized in a discussion
document for the Wrst workshop held during the annual
CIC/CRI meeting in Washington DC in March 2010. For
this public workshop, expert panelists from diVerent immu-
nology Welds (cancer, infectious diseases, autoimmunity),
regulatory agencies, and journal editors were invited to dis-
cuss the initial guideline draft and comments received, and
to update MIATA to version 1.
It became clear that general questions had to be
addressed and consensus had to be reached Wrst, before the
speciWc content could be tackled. SpeciWcally, the follow-
ing topics were intensely discussed during the workshop:
1. Scope of MIATA (framework for scientiWc publica-
tions vs. annotations for data base eVorts)
2. Focused application for the MIATA publication frame-
work (human immune monitoring versus T cell
immune assays in general)
3. Striking a balance between minimal and suYcient
information
4. The importance of freedom of research.
In eVect, the focus of MIATA was re-deWned and speciWed
as a reporting framework for scientiWc publications of
human immune monitoring results. After its successful
implementation for the described purpose, MIATA should
be adaptable in a step-wise manner to support annotations
of immune monitoring data sets, for example in the context
of a Human Immunity Project [24]. It needs to be stressed
Fig. 1 Pathway for achieving 
high quality and acceptance 
among peers. A step-wise and 
open process was initiated for 
MIATA. A dedicated indepen-
dent website was launched and 
public consultation periods, 
workshops, and webinars are 
being conducted to achieve 
technical precision, user-
friendliness, adequate 
incorporation of concerns, high 
acceptance rates among peers, 
an ultimately maximum value 
for the scientiWc community123
20 Cancer Immunol Immunother (2011) 60:15–22that the consensus reached on these topics was found to be
of the utmost importance for the increasing acceptance and
continuation of MIATA.
Subsequently, the speciWc content of the guidelines was
discussed by reviewing each single sub-module and related
comments received. Due to the volume of information and
impressive amount of feedback obtained, this process was
extended over the remaining workshop and three separate
webinars. A consensus was reached on the basis of profes-
sional discussions among panelists, and in consequence the
MIATA guidelines were upgraded to Version 1 [18], parts
of which diVer considerably from the original draft.
Next steps and future perspectives
As for the initial guidelines, the updated MIATA modules
have been posted on the project’s web site, and the Weld is
once again invited to review and comment on its content.
The Wrst feedback already received indicates increasing
agreement with the current framework. Most of the pro-
posed changes and additions focus on single sub-modules.
In addition to soliciting further comments on the
MIATA Version 1 guidelines, the current focus of the core
team is to increase general awareness of the project in the
Weld. In parallel, eVorts are underway to promote the adop-
tion of MIATA by scientists and journals. The MIATA
experience has demonstrated that surprisingly little knowl-
edge exists among immunologists about Minimal Informa-
tion concepts and existing projects. Several recent articles
addressing publication guidelines for optimized multicolor
immunoXuorescence panels might aid in raising further
awareness [32]. Keeping the high value of these projects in
mind, it is important to disseminate information about them
and at the same time initiate collaborations among all stake-
holders and MI projects that overlap in any way with
MIATA. This will help to avoid duplication of eVort or
even competition, while oVering guidance to the commu-
nity in their choice of the most suitable assays and imple-
mentation of the appropriate frameworks in their scientiWc
work.
The current MIATA Version 1 is the result of a highly
collaborative eVort. It is essential for the success of this
project to promote the further input of the community and
to enhance the discussion and Wnal consensus between sci-
entists and scientiWc journals.
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